Healthcare / BiotechnologyOslo
$21.20
-1.30 (-5.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $5.2M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
81.5x
↑EV/EBITDA
42.1x
↑ROE
2.9%
↑Gross Margin
95.7%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.3%
FCF CAGR
-21.6%
FCF margin
19.7%
FCF / Net income
2.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $112.6M · net income $9.7M · FCF $22.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $112.6M | $112.6M | $104.4M | $118.9M | $137.0M |
| Net Income | $9.7M | $9.7M | $8.5M | $19.4M | $32.9M |
| EBITDA | $21.4M | $21.4M | $17.5M | $31.6M | $47.8M |
| EPS | 0.19 | 0.19 | 0.17 | 0.38 | 0.65 |
| Gross Margin | 95.7% | 95.7% | 94.3% | 95.0% | 96.2% |
| Operating Margin | 2.3% | 2.3% | -1.4% | 13.2% | 26.6% |
| Net Margin | 8.6% | 8.6% | 8.1% | 16.3% | 24.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.04 | 0.05 |
| Current Ratio | 15.83 | 15.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $22.2M | $22.2M | $-7.9M | $5.2M | $45.9M |
| Returns | |||||
| ROE | 2.9% | 2.9% | 2.6% | 6.3% | 11.5% |
| Valuation | |||||
| P/E | 81.54 | 81.54 | 82.71 | 105.26 | 82.00 |
| EV/EBITDA | 42.10 | 42.10 | 31.76 | 59.02 | 53.33 |
| P/B | 3.20 | 3.20 | 2.21 | 6.58 | 9.53 |
| Growth & Yield | |||||
| Revenue Growth | 7.9% | 7.9% | -12.3% | -13.2% | — |
| EPS Growth | 11.8% | 11.8% | -55.3% | -41.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
114.7%
EPS terminal req.
$1.88
Spread vs growth
-103.0%
5Y implied EPS CAGR
64.3%
EPS terminal req.
$2.28
Spread vs growth
-52.6%
10Y implied EPS CAGR
34.4%
EPS terminal req.
$3.67
Spread vs growth
-22.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+30.9%
Start / end P/E
95.3x → 111.6x
EPS bridge
0.17 → 0.19
Residual
+2.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.